JOHN R. COTE, PHARM. D.
To the editor: Easton, in his review article (1), stated, "Evidence suggests that there is little place for the use of intramuscular diphenylhydantoin." It is clear that his review of the literature concerning intramuscular administration of diphenylhydantoin was not complete. His bibliography included the works of Wallis, Kutt, and McDowell (2), as well as Dam and Olsen (3), but did not include the study by Cantu, Schwab, and Timberlake (4).
Wallis, Kutt, and McDowell reported a low serum level of diphenylhydantoin for 24 hours after a single intramuscular dose of 500 mg. This may be explained by the pharmacokinetics of
COTE JR. Intramuscular Diphenylhydantoin. Ann Intern Med. ;78:980–981. doi: 10.7326/0003-4819-78-6-980
Download citation file:
Published: Ann Intern Med. 1973;78(6):980-981.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use